Uveitis is one of the common blinding eye diseases in China. According to incomplete statistics, there are 3-4 million patients with uveitis in China, of which 10% lead to serious visual dysfunction or even blindness, accounting for 3-7th of the blinding eye diseases in China. Uveitis has more than 150 causes and is one of the most common and difficult diseases in ophthalmology because it occurs mainly in young adults and has a long course and is prone to recurrence. However, there are few doctors in China who specialize in the research and treatment of uveitis, and many old treatment routines are still widely used in major hospitals, which affects the treatment and prognosis of many patients, thus, many treatment concepts need to be updated. An important pathological manifestation of uveitis is the inflammation of the iris, which leads to a large amount of exudate in the front of the eye and adhesions between the iris and the lens, which in turn affects atrial flow and causes glaucoma, the main cause of blindness in many patients with uveitis. As a result, clinicians are very concerned about the severe anterior chamber exudate and iris adhesions caused by uveitis, and past treatment routines have often involved ocular injections of “hormones” in an attempt to get the drug into the eye as quickly as possible and with maximum effectiveness. In fact, many “hormonal” eye drops can rapidly penetrate through the ocular surface and enter the eye, so choosing the correct concentration and type of eye drops and administering them with the proper frequency can achieve rapid inflammation control. The effect is no different from that of periocular injections of “hormones”. However, in terms of side effects, ocular injections can cause damage to the periocular tissues, scarring, bleeding and other complications, and medical accidents caused by needles accidentally entering the eye during injection have also occurred from time to time. Despite the use of surface anesthetics for ocular injections, many patients still have a fear of the pain they cause, and the pain can become increasingly intense after repeated injections. Therefore, the concept that topical eye drops are a completely effective, safe and reliable treatment and that there is no need for ocular injections for patients has long been widely accepted by ophthalmologists abroad, while in China, including many large specialty hospitals, the previous ocular injection method is still widely used. The use of pupil dilators is important in controlling ocular inflammation and avoiding secondary glaucoma caused by iris adhesions, however incorrect selection of medication and mode of administration can be just as harmful. The main purpose of using a pupil dilator is to prevent iris adhesions, which requires that the iris be kept in motion under the action of the dilator, rather than just pursuing a dilated pupil. It is common to see the use of atropine to dilate the pupil for a long period of time, while the iris is dilated and iris adhesions occur, causing the pupil to fail to retract, resulting in long-term photophobia and glare. Therefore, we advocate the use of short-acting, fast-acting pupil dilators in our treatment, and adjust the frequency and intensity of eye dots to achieve the purpose of moving the pupil. In recent years, as the research and understanding of ocular uveitis has progressed, the pathogenesis of the disease has been more accurately understood, and there have been many advances in treatment that differ greatly from those of the past. There are many concepts that need to be updated in the treatment of ocular uveitis, both in terms of efficacy and the side effects and compliance associated with the treatment modality. I was prompted to think about the treatment of a beautiful young woman with recurrent ocular uveitis caused by “compulsive spondylitis” who had had four episodes in the past two years, each time at a famous ophthalmology hospital in Beijing. Each time she saw a doctor, she had to undergo several consecutive eye injections. Although she got better with this treatment every time she had an attack, the pain from the eye injections caused her a deep fear, so every time she had an attack, the thought of the treatment she would face would cause a strong reaction, and she had a serious psychological burden about her eye disease. By chance, the patient came to our ophthalmology department on an errand near our hospital and was seen by me at that time. On examination, her eye disease was in a severe flare-up, with severe inflammatory exudation and iris adhesions. After I examined her, the patient asked fearfully if she needed an “eye injection”, but I told her clearly that she did not need one and that the eye drops would control it. After hearing my words, the patient was half-hearted, but she was happy to hear that she did not need an “eye injection” because she was too afraid of it. Under my careful treatment, the patient’s inflammation was quickly controlled and the iris adhesions disappeared without a single “eye injection”. “. I hope that more ophthalmologists will embrace the new concept of uveitis treatment so that more eye patients can be cured in a “painless” way.